PURPOSE: For patients with relapsed or refractory aggressive lymphoma, we hypothesized that gemcitabine-based therapy before autologous stem-cell transplantation (ASCT) is as effective as and less toxic than standard treatment. PATIENTS AND METHODS: We randomly assigned 619 patients with relapsed/refractory aggressive lymphoma to treatment with gemcitabine, dexamethasone, and cisplatin (GDP) or to dexamethasone, cytarabine, and cisplatin (DHAP). Patients with B-cell lymphoma also received rituximab. Responding patients proceeded to stem-cell collection and ASCT. Coprimary end points were response rate after two treatment cycles and transplantation rate. The noninferiority margin for the response rate to GDP relative to DHAP was set at 10%. Secondary end points included event-free and overall survival, treatment toxicity, and quality of life. RESULTS: For the intention-to-treat population, the response rate with GDP was 45.2%; with DHAP the response rate was 44.0% (95% CI for difference, -9.0% to 6.7%), meeting protocol-defined criteria for noninferiority of GDP (P = .005). Similar results were obtained in a per-protocol analysis. The transplantation rates were 52.1% with GDP and 49.3% with DHAP (P = .44). At a median follow-up of 53 months, no differences were detected in event-free survival (HR, 0.99; stratified log-rank P = .95) or overall survival (HR, 1.03; P = .78) between GDP and DHAP. Treatment with GDP was associated with less toxicity (P < .001) and need for hospitalization (P < .001), and preserved quality of life (P = .04). CONCLUSION: For patients with relapsed or refractory aggressive lymphoma, in comparison with DHAP, treatment with GDP is associated with a noninferior response rate, similar transplantation rate, event-free survival, and overall survival, less toxicity and hospitalization, and superior quality of life.

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12 / Crump, Michael; Kuruvilla, John; Couban, Stephen; Macdonald, David A; Kukreti, Vishal; Kouroukis, C. Tom; Rubinger, Morel; Buckstein, Rena; Imrie, Kevin R; Federico, Massimo; Di Renzo, Nicola; Howson Jan, Kang; Baetz, Tara; Kaizer, Leonard; Voralia, Michael; Olney, Harold J; Turner, A. Robert; Sussman, Jonathan; Hay, Annette E; Djurfeldt, Marina S; Meyer, Ralph M; Chen, Bingshu E; Shepherd, Lois E.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 32 (31)(2014), pp. 3490-3496. [10.1200/JCO.2013.53.9593]

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12

FEDERICO, Massimo;
2014

Abstract

PURPOSE: For patients with relapsed or refractory aggressive lymphoma, we hypothesized that gemcitabine-based therapy before autologous stem-cell transplantation (ASCT) is as effective as and less toxic than standard treatment. PATIENTS AND METHODS: We randomly assigned 619 patients with relapsed/refractory aggressive lymphoma to treatment with gemcitabine, dexamethasone, and cisplatin (GDP) or to dexamethasone, cytarabine, and cisplatin (DHAP). Patients with B-cell lymphoma also received rituximab. Responding patients proceeded to stem-cell collection and ASCT. Coprimary end points were response rate after two treatment cycles and transplantation rate. The noninferiority margin for the response rate to GDP relative to DHAP was set at 10%. Secondary end points included event-free and overall survival, treatment toxicity, and quality of life. RESULTS: For the intention-to-treat population, the response rate with GDP was 45.2%; with DHAP the response rate was 44.0% (95% CI for difference, -9.0% to 6.7%), meeting protocol-defined criteria for noninferiority of GDP (P = .005). Similar results were obtained in a per-protocol analysis. The transplantation rates were 52.1% with GDP and 49.3% with DHAP (P = .44). At a median follow-up of 53 months, no differences were detected in event-free survival (HR, 0.99; stratified log-rank P = .95) or overall survival (HR, 1.03; P = .78) between GDP and DHAP. Treatment with GDP was associated with less toxicity (P < .001) and need for hospitalization (P < .001), and preserved quality of life (P = .04). CONCLUSION: For patients with relapsed or refractory aggressive lymphoma, in comparison with DHAP, treatment with GDP is associated with a noninferior response rate, similar transplantation rate, event-free survival, and overall survival, less toxicity and hospitalization, and superior quality of life.
32 (31)
3490
3496
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12 / Crump, Michael; Kuruvilla, John; Couban, Stephen; Macdonald, David A; Kukreti, Vishal; Kouroukis, C. Tom; Rubinger, Morel; Buckstein, Rena; Imrie, Kevin R; Federico, Massimo; Di Renzo, Nicola; Howson Jan, Kang; Baetz, Tara; Kaizer, Leonard; Voralia, Michael; Olney, Harold J; Turner, A. Robert; Sussman, Jonathan; Hay, Annette E; Djurfeldt, Marina S; Meyer, Ralph M; Chen, Bingshu E; Shepherd, Lois E.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 32 (31)(2014), pp. 3490-3496. [10.1200/JCO.2013.53.9593]
Crump, Michael; Kuruvilla, John; Couban, Stephen; Macdonald, David A; Kukreti, Vishal; Kouroukis, C. Tom; Rubinger, Morel; Buckstein, Rena; Imrie, Kevin R; Federico, Massimo; Di Renzo, Nicola; Howson Jan, Kang; Baetz, Tara; Kaizer, Leonard; Voralia, Michael; Olney, Harold J; Turner, A. Robert; Sussman, Jonathan; Hay, Annette E; Djurfeldt, Marina S; Meyer, Ralph M; Chen, Bingshu E; Shepherd, Lois E.
File in questo prodotto:
File Dimensione Formato  
JCO-2014-Crump-3490-6.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 187.65 kB
Formato Adobe PDF
187.65 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1066211
Citazioni
  • ???jsp.display-item.citation.pmc??? 92
  • Scopus 250
  • ???jsp.display-item.citation.isi??? 242
social impact